Grail, Inc. (NL0)
XSTU
Real-time Data
06:00 AM
Day's Range
67.2052 wk Range
26.70Overview - NL0 - Grail, Inc.
Key Statistics
Valuation
Enterprise Value
1.92B
P/E (Trailing)
‪-6.24‬
PEG Ratio
‪0.32‬
Price / Sales (TTM)
‪18.27‬
Price / Book
‪1.37‬
EV / EBITDA
‪-5.94‬
Profitability
Gross Margin
‪-28.12%‬
Profit Margin
‪-236.94%‬
Operating Margin
‪-331.99%‬
Return on Assets
‪-12.03%‬
Return on Equity
‪-16.12%‬
Ownership
Shares Outstanding
44.66M
Float
34.28M
Held by Insiders
‪5.02%‬
Held by Institutions
‪86.77%‬
Price stats
Beta
‪3.24‬
50-Day Avg
‪59.53‬
200-Day Avg
‪62.48‬
Dividends
Payout Ratio
‪0.00%‬
Peers - NL0 - Grail, Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on XSTU.
- NL0XSTUGrail, Inc.3.00BMarket Cap+57.60%52-week change-6.08P/E (Trailing)‪-236.94%‬Profit Margin
- 1K9XSTUCareDx Inc.947.04MMarket Cap+11.07%52-week change-48.00P/E (Trailing)‪67.55%‬Profit Margin
- EGQ0XSTUINOVIQ Limited15.48MMarket Cap-81.82%52-week change-1.77P/E (Trailing)‪0.00%‬Profit Margin
- LMQXSTUOxford Biodynamics Plc978.78KMarket Cap-800.00%52-week change-0.13P/E (Trailing)‪47.67%‬Profit Margin
Profile Summary - NL0 - Grail, Inc.
About
Grail, Inc. is a biotechnology company headquartered in Menlo Park, California, founded in 2015. The company focuses on alleviating the global burden of cancer through innovative multi-cancer early detection technologies. Its flagship product, the Galleri test, is a blood-based liquid biopsy that screens for multiple…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
